News for Evaxion Biotech A/S (EVAX)

Operator: Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine

Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S ( EVAX) (”œEvaxion”), a clinical-sta

The following slide deck was published by Evaxion Biotech A/S in conjunction with their 2024 Q4 earnings call.

**media[582615]**

**media[581055]**

**media[576524]**

Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months COPENHAGEN, Denmark, March 4, 2

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year

**media[540788]**

Shares of Palantir Technologies Inc. PLTR rose sharply in today's pre-market trading following better-than-expected fourth-quarter results. Palantir reported f...

**media[529336]**

Shares of Twilio Inc. TWLO rose sharply in today's pre-market trading after the company provided preliminary financial results for the fourth quarter. After th...

Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S ( EVAX) (”œEvaxi

COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S ( EVAX) (”œEvaxion” or the ”œCompany”), a clinical-stage TechBio company specializing in devel

**media[515156]**

COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S ( EVAX) (”œEvaxion”), a clinical-stage TechBio company specializing in developing AI-Immunologyâ„

COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S ( EVAX) (”œEvaxion”), a clinical-stage TechBio company specializing in developing AI-Immunologyâ

Editor’s note: This story has been corrected to state that Castellum Inc — not Constellium SE — announced the pricing of a public stock offering. With U....